{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T18:19:36Z","timestamp":1787941176933,"version":"build-2784847793"},"reference-count":29,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Kyowa Kirin Co., Ltd."},{"name":"Kyowa Kirin Co., Ltd."},{"name":"Kyowa Kirin Co., Ltd."},{"name":"Kyowa Kirin Co., Ltd."},{"name":"Kyowa Kirin Co., Ltd."}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"Tenapanor hydrochloride (tenapanor), a selective inhibitor of the sodium\/hydrogen exchanger isoform 3, is approved for management of hyperphosphatemia in patients undergoing dialysis. Dosage is initiated at 5 mg twice daily and can be titrated to 10, 20, or 30 mg twice daily according to clinical response and tolerability. However, patient characteristics associated with the need for higher tenapanor doses remain unclear. This study is a pooled analysis of data from three clinical trials conducted in Japan, in which tenapanor dose was titrated starting from 5 mg twice daily. After 8 weeks of treatment, dialysis patients were retrospectively categorized into a low-dose group (5 or 10 mg\/dose; n\u2009=\u2009127) and a high-dose group (20 or 30 mg\/dose; n\u2009=\u200985) according to their final dose. Univariate and multivariate analyses were performed to identify baseline factors independently associated with higher tenapanor dose requirements. At Week 8, mean\u2009\u00b1\u2009standard deviation tenapanor dose was 8.0\u2009\u00b1\u20092.5 mg twice daily in the low-dose group, and 26.7\u2009\u00b1\u20094.9 mg twice daily in the high-dose group. Serum phosphorus levels decreased gradually over 8 weeks in both groups; however, no significant between-group difference in change from baseline was observed. Baseline comparisons showed significant differences in serum phosphorus, serum tartrate-resistant acid phosphatase 5b (TRACP-5b), number of concomitant phosphate binders, use of sevelamer hydrochloride and laxatives, and Bristol Stool Form Scale (BSFS) scores. Multivariate analysis identified serum TRACP-5b as a significant positive independent predictor and BSFS score as a significant negative independent predictor for requiring higher doses of tenapanor. Elevated TRACP-5b levels and lower BSFS scores were associated with a requirement for higher doses of tenapanor. Incorporating bone turnover and bowel habit assessments into clinical evaluations may support individualized dosing strategies. Large-scale prospective studies in real-world settings are warranted to confirm these findings.<\/jats:p>\n \n Trial registration<\/jats:title>\n \n The original clinical trials were registered at ClinicalTrials.gov under the identifiers\n NCT04767581<\/jats:ext-link>\n ,\n NCT04766398<\/jats:ext-link>\n , and\n NCT04766385<\/jats:ext-link>\n .\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1371\/journal.pone.0356873","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T17:52:56Z","timestamp":1787939576000},"page":"e0356873","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient characteristics associated with the need for high doses of tenapanor hydrochloride in dialysis patients with hyperphosphatemia: A pooled analysis of three clinical trials"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6527-3286","authenticated-orcid":true,"given":"Nobuo","family":"Nagano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Tokunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7717-8945","authenticated-orcid":true,"given":"Shinji","family":"Asada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Fukagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadao","family":"Akizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"issue":"8","key":"pone.0356873.ref001","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/j.ekir.2021.05.012","article-title":"Phosphate balance and CKD-mineral bone disease","volume":"6","author":"SM Sprague","year":"2021","journal-title":"Kidney Int Rep"},{"issue":"3","key":"pone.0356873.ref002","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000516286","article-title":"Phosphate control: the next frontier in dialysis cardiovascular mortality","volume":"11","author":"PA McCullough","year":"2021","journal-title":"Cardiorenal Med"},{"issue":"9","key":"pone.0356873.ref003","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.3390\/nu17091587","article-title":"Hyperphosphatemia in kidney failure: pathophysiology, challenges, and critical role of phosphorus management","volume":"17","author":"S Raju","year":"2025","journal-title":"Nutrients"},{"key":"pone.0356873.ref004","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.2147\/PPA.S145648","article-title":"Phosphate-control adherence in hemodialysis patients: current perspectives","volume":"12","author":"EM Umeukeje","year":"2018","journal-title":"Patient Prefer Adherence"},{"key":"pone.0356873.ref005","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2147\/IJNRD.S318593","article-title":"Multidisciplinary perspectives of current approaches and clinical gaps in the management of hyperphosphatemia","volume":"14","author":"M Vall\u00e9e","year":"2021","journal-title":"Int J Nephrol Renovasc Dis"},{"issue":"6","key":"pone.0356873.ref006","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1111\/1744-9987.13813","article-title":"Impact of phosphate binders on medication dosing frequency, timing, and number of prescribed pills in hemodialysis patients","volume":"26","author":"N Nagano","year":"2022","journal-title":"Ther Apher Dial"},{"issue":"6","key":"pone.0356873.ref007","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.2215\/CJN.00290109","article-title":"Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients","volume":"4","author":"Y-W Chiu","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"pone.0356873.ref008","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1093\/ndt\/gft280","article-title":"Serum phosphorus levels and pill burden are inversely associated with adherence in patients on hemodialysis","volume":"29","author":"S Wang","year":"2014","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"pone.0356873.ref009","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/hdi.12315","article-title":"Phosphate binder pill burden, patient-reported non-adherence, and mineral bone disorder markers: findings from the DOPPS","volume":"20","author":"RB Fissell","year":"2016","journal-title":"Hemodial Int"},{"key":"pone.0356873.ref010","doi-asserted-by":"crossref","first-page":"475","DOI":"10.4009\/jsdt.49.475","article-title":"The prescription of a higher number of phosphate binder pills is associated with lower medication adherence and worse serum phosphorus control","volume":"49","author":"K Ito","year":"2016","journal-title":"J Jpn Soc Dial Ther"},{"key":"pone.0356873.ref011","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s41100-021-00322-2","article-title":"Prescription characteristics of phosphate binders in a high pill burden for hemodialysis patients","volume":"7","author":"N Nagano","year":"2021","journal-title":"Ren Replace Ther"},{"issue":"2","key":"pone.0356873.ref012","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/1744-9987.14241","article-title":"Tenapanor: a novel therapeutic agent for dialysis patients with hyperphosphatemia","volume":"29","author":"T Akizawa","year":"2025","journal-title":"Ther Apher Dial"},{"issue":"7","key":"pone.0356873.ref013","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1021\/acsmedchemlett.2c00037","article-title":"Discovery of tenapanor: a first-in-class minimally systemic inhibitor of intestinal Na+\/H+ exchanger isoform 3","volume":"13","author":"JW Jacobs","year":"2022","journal-title":"ACS Med Chem Lett"},{"issue":"456","key":"pone.0356873.ref014","article-title":"Inhibition of sodium\/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability","volume":"10","author":"AJ King","year":"2018","journal-title":"Sci Transl Med"},{"issue":"2","key":"pone.0356873.ref015","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ekir.2021.11.008","article-title":"Dose-response of tenapanor in patients with hyperphosphatemia undergoing hemodialysis in japan-a phase 2 randomized trial","volume":"7","author":"M Inaba","year":"2022","journal-title":"Kidney Int Rep"},{"issue":"9","key":"pone.0356873.ref016","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1016\/j.ekir.2021.06.030","article-title":"Effect of tenapanor on phosphate binder pill burden in hemodialysis patients","volume":"6","author":"T Akizawa","year":"2021","journal-title":"Kidney Int Rep"},{"issue":"6","key":"pone.0356873.ref017","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1159\/000516156","article-title":"Therapeutic effects of add-on tenapanor for hemodialysis patients with refractory hyperphosphatemia","volume":"52","author":"T Shigematsu","year":"2021","journal-title":"Am J Nephrol"},{"issue":"5","key":"pone.0356873.ref018","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1053\/j.ajkd.2023.03.019","article-title":"Tenapanor for the treatment of hyperphosphatemia in japanese hemodialysis patients: a randomized phase 3 monotherapy study with an up-titration regimen","volume":"82","author":"M Fukagawa","year":"2023","journal-title":"Am J Kidney Dis"},{"issue":"11","key":"pone.0356873.ref019","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1016\/j.ekir.2023.08.003","article-title":"Randomized study of tenapanor added to phosphate binders for patients with refractory hyperphosphatemia","volume":"8","author":"K Nitta","year":"2023","journal-title":"Kidney Int Rep"},{"issue":"2","key":"pone.0356873.ref020","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10157-023-02406-1","article-title":"Tenapanor for peritoneal dialysis patients with hyperphosphatemia: a phase 3 trial","volume":"28","author":"M Nakayama","year":"2024","journal-title":"Clin Exp Nephrol"},{"issue":"1","key":"pone.0356873.ref021","doi-asserted-by":"crossref","first-page":"19100","DOI":"10.1038\/s41598-023-45080-9","article-title":"Long-term safety and decrease of pill burden by tenapanor therapy: a phase 3 open-label study in hemodialysis patients with hyperphosphatemia","volume":"13","author":"F Koiwa","year":"2023","journal-title":"Sci Rep"},{"issue":"3","key":"pone.0356873.ref022","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/1744-9987.12058","article-title":"Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder","volume":"17","author":"M Fukagawa","year":"2013","journal-title":"Ther Apher Dial"},{"issue":"4","key":"pone.0356873.ref023","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/s00223-008-9127-4","article-title":"Serum levels of TRAP5b, a new bone resorption marker unaffected by renal dysfunction, as a useful marker of cortical bone loss in hemodialysis patients","volume":"82","author":"K Shidara","year":"2008","journal-title":"Calcif Tissue Int"},{"issue":"3","key":"pone.0356873.ref024","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.pharmthera.2005.06.019","article-title":"Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism","volume":"109","author":"N Nagano","year":"2006","journal-title":"Pharmacol Ther"},{"issue":"9","key":"pone.0356873.ref025","doi-asserted-by":"crossref","first-page":"920","DOI":"10.3109\/00365529709011203","article-title":"Stool form scale as a useful guide to intestinal transit time","volume":"32","author":"SJ Lewis","year":"1997","journal-title":"Scand J Gastroenterol"},{"issue":"11","key":"pone.0356873.ref026","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3390\/jcm6110099","article-title":"Rome Criteria and a Diagnostic Approach to Irritable Bowel Syndrome","volume":"6","author":"BE Lacy","year":"2017","journal-title":"J Clin Med"},{"issue":"227","key":"pone.0356873.ref027","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007790","article-title":"Intestinal inhibition of the Na+\/H+ exchanger 3 prevents cardiorenal damage in rats and inhibits Na+ uptake in humans","volume":"6","author":"AG Spencer","year":"2014","journal-title":"Sci Transl Med"},{"key":"pone.0356873.ref028","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s41100-025-00648-1","article-title":"Efficacy of tenapanor hydrochloride for hyperphosphatemia in hemodialysis patients: a single-center retrospective observational study","volume":"11","author":"M Okamura","year":"2025","journal-title":"Ren Replace Ther"},{"issue":"6","key":"pone.0356873.ref029","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0319319","article-title":"Efficacy of tenapanor in managing hyperphosphatemia and constipation in hemodialysis patients: a randomized controlled trial","volume":"20","author":"N Suzuki","year":"2025","journal-title":"PLoS One"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0356873","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T17:53:09Z","timestamp":1787939589000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0356873"}},"subtitle":[],"editor":[{"given":"Ken","family":"Iseri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":29,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8,28]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0356873","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]}}}